Carcinoma, Non-Small-Cell Lung: all 6,641 studies
Page 13 of 67. Open to participants first (1,665), then studies with results posted, then the rest; newest registration first within each.
- Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung CancerNot yet recruitingNCT05978401Phase 1/2
- MONDRIAN: Multi-omics Integrative Modelling for Stereotactic Body Radiotherapy in Early-stage Non-small Cell Lung CancerRecruitingNCT05974475
- Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLCRecruitingNCT05974007
- Tirellizumab Combined With Chemotherapy Monotherapy for Non-small Cell Lung CancerNot yet recruitingNCT05965102Phase 1
- Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung CancerRecruitingNCT05965024
- Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR MutationNot yet recruitingNCT05962021Phase 2
- Effect of Exercise Therapy on Psychological State and Clinical Prognosis of Advanced Non-small Cell Lung CancerNot yet recruitingNCT05959265Not applicable
- A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsRecruitingNCT05956587Phase 2
- Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLCRecruitingNCT05950139Phase 1/2
- A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid TumorsRecruitingNCT05948865Phase 1
- A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLCRecruitingNCT05940532Phase 2
- A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid TumorsNot yet recruitingNCT05940116Phase 1
- Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.RecruitingNCT05937906Phase 1/2
- SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuationRecruitingNCT05935384
- National Network Genomic Medicine Lung Cancer, GermanyRecruitingNCT05934032
- Macrophage Imaging Using Ga-MMR-VHH2 in Lung Cancer PatientsRecruitingNCT05933239Phase 2
- Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung CancerNot yet recruitingNCT05932264Phase 2
- Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung CancerRecruitingNCT05925751
- Deep Learning Signature for Predicting Aggressive Histological Pattern in Resected Non-small Cell Lung CancerRecruitingNCT05925738
- Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.RecruitingNCT05922345Phase 3
- Detection of Circulating Tumor DNA After Stereotactic Ablative Radiotherapy in Patients With Unbiopsied Lung TumorsRecruitingNCT05921474
- A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)RecruitingNCT05920356Phase 3
- LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRTRecruitingNCT05919641
- A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid TumorsRecruitingNCT05914116Phase 1/2
- A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung CancerRecruitingNCT05913089Phase 2
- A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell CancersRecruitingNCT05910827Phase 1/2
- Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLCNot yet recruitingNCT05910034Phase 2
- Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung CancerNot yet recruitingNCT05900921Phase 2
- Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical StudyNot yet recruitingNCT05900219Phase 2
- CIETAI and Sequential Radiotherapy in Squamous Lung CancerRecruitingNCT05892237Phase 2
- Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 TrialNot yet recruitingNCT05891080Phase 2
- MYLUNG Consortium Part 3: Observational StudyRecruitingNCT05885698
- L-TIL Plus Tislelizumab for PD1 Antibody Resistant aNSCLCRecruitingNCT05878028Phase 2
- A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H MutationRecruitingNCT05877599Phase 1
- Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)RecruitingNCT05872867Phase 1
- Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKIRecruitingNCT05869162Phase 2
- A Study of Oncobax®-AK in Patients With Advanced Solid TumorsRecruitingNCT05865730Phase 2
- A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)RecruitingNCT05865002Phase 1
- A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT05863325Phase 2
- Use of the ADL-Glittre Test in the Pre and Postoperative Period of Patients With Lung CancerEnrolling by invitationNCT05863013Not applicable
- A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)Not yet recruitingNCT05859217Phase 2
- Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid TumorsRecruitingNCT05856981Phase 1
- Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLCRecruitingNCT05852990Phase 3
- Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 AlterationsNot yet recruitingNCT05847764Phase 2
- Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)Not yet recruitingNCT05842018Phase 2
- Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerRecruitingNCT05841472Phase 2
- A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft TissueRecruitingNCT05837767Not applicable
- A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLCRecruitingNCT05837052Phase 2
- Integrin αvβ6-targeted PET in Malignant TumorsRecruitingNCT05835570
- Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint InhibitorsRecruitingNCT05834413Not applicable
- Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell CarcinomaRecruitingNCT05830058Phase 2
- ctDNA-MRD in Stage IIIB-C NSCLC Patients Treated With Induction ChemoimmunotherapyNot yet recruitingNCT05822284
- RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLCRecruitingNCT05821933Phase 1/2
- Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLCEnrolling by invitationNCT05813522Phase 2
- Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain MetastasesNot yet recruitingNCT05812534Phase 2
- Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLCRecruitingNCT05805631Phase 2
- Dietary Intervention for NSCLC Patients Treated With ICIRecruitingNCT05805319Not applicable
- Lung Cancer Multi-omics Digital Human Avatars for Integrating Precision Medicine Into Clinical PracticeNot yet recruitingNCT05802771
- Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI StudyRecruitingNCT05802186Not applicable
- From Benchmark to Surgical Activity: the Role of Endobronchial Fiducial Markers for Ground Glass Lung Nodules Resection.Not yet recruitingNCT05801406
- Dose Attenuated Chemotherapy in Compromised Patients With Lung CancerRecruitingNCT05800587Phase 2
- Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLCRecruitingNCT05800340Phase 2
- Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung CancerRecruitingNCT05800223Phase 3
- A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C MutationRecruitingNCT05789082Phase 1/2
- Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesRecruitingNCT05786924Phase 1/2
- A Study of DB-1310 in Advanced/Metastatic Solid TumorsRecruitingNCT05785741Phase 1/2
- Study of Polymeric Micellar Paclitaxel, Platinum Combined With Sindilizumab Injection for Advanced Non-squamous NSCLCNot yet recruitingNCT05782426Phase 2
- Tai-Chi and Aerobic Exercise to Improve Emotional Symptom Cluster in Late-stage Lung Cancer PatientsRecruitingNCT05778708Not applicable
- Examination of Trends in Non-Small Cell Lung Cancer Patients' Medical Study ExperiencesNot yet recruitingNCT05778045
- Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET OverexpressionRecruitingNCT05777278Phase 1/2
- DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.RecruitingNCT05768178Phase 2/3
- YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion MutationsNot yet recruitingNCT05767892Phase 3
- Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung CancerRecruitingNCT05766800Phase 2
- Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung CancerRecruitingNCT05765877Phase 2
- Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.RecruitingNCT05754736Phase 2
- Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid TumoursRecruitingNCT05752552Phase 1
- Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or LymphomasRecruitingNCT05751798Phase 1/2
- Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung CancerRecruitingNCT05751018Phase 2
- Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With CobicistatRecruitingNCT05748093Phase 4
- A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 MutationNot yet recruitingNCT05745740Phase 1/2
- IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)RecruitingNCT05742607Phase 2
- Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using MultiomicsRecruitingNCT05736029
- A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of RelapseRecruitingNCT05732974
- Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)RecruitingNCT05724004Not applicable
- TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.Not yet recruitingNCT05718167Phase 3
- BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung CancerNot yet recruitingNCT05715398Phase 1/2
- Alectinib Pharmacokinetic in Patients With NSCLCRecruitingNCT05713006Phase 1/2
- A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South KoreaRecruitingNCT05703516
- Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare MutationsRecruitingNCT05701787
- A Pilot Study to Understand the Impact of Therapy With Tumour Treating Fields (TTFields) in NSCLCNot yet recruitingNCT05698264Not applicable
- Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid TumoursNot yet recruitingNCT05698238Phase 1
- Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung CancerRecruitingNCT05696782Phase 2
- Reducing the Incidence of Symptomatic Brain Metastases With MRI SurveillanceRecruitingNCT05692635Phase 2
- SILibinin in NSCLC and BC Patients With Single Brain METastasis (SILMET)RecruitingNCT05689619Not applicable
- Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)RecruitingNCT05686434Phase 2
- Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLCRecruitingNCT05681780Phase 1
- A Study of TY-1091 in Patients With Advanced Solid TumorsRecruitingNCT05675605Phase 1/2
- Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerRecruitingNCT05673590Phase 3
- Phase II Trial of Lung ChemoemobolizationRecruitingNCT05672108Phase 2
- Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLCRecruitingNCT05669846Phase 2